Moderna switches to launch mode

Posted 16 September 2024 AM

Moderna is downplaying the impact on its Australian business of a global decision to slow down investment in R&D - cancelling five programs - while it focuses on launching products that have reached the commercial stage.

The company told investors it is at a "key pivot point" and intends to throw its focus on the commercial challenge of launching of 10 products over just three years. And Australia, home to one of the mRNA giant's manufacturing plants, may benefit from the pivot.

To see the whole article, please login